4 recruiting. 2 Early Phase 1, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Recruiting 2 |
| Phase 1 | 2 | Recruiting 2 |
Follow CytoCares Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CC312 for Relapsed/Refractory Autoimmune Diseases CC312 - SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | CytoCares Inc | 6 | 2025-09-23 | 2026-04-14 |
| Safety and Efficacy Study of CC312 for Moderate to Severe SLE CC312, Placebo - SLE - Systemic Lupus Erythematosus | Phase 1 | Recruiting | CytoCares Inc | 32 | 2025-09-11 | 2025-09-17 |
| Safety Study of CC312 in Autoimmune Disease Patients CC312 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | Early Phase 1 | Recruiting | CytoCares Inc | 18 | 2024-11-08 | 2025-09-17 |
| Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies CC312 - Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia | Phase 1 | Recruiting | CytoCares Inc | 44 | 2023-08-07 | 2025-09-22 |
Lupus Erythematosus, Systemic (3) · Anemia, Hemolytic, Autoimmune (1) · Arthritis, Rheumatoid (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myositis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Scleroderma, Systemic (1)
China (4)